A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

Just over a month af­ter strik­ing a deal with No­var­tis to bring its PD-1 an­ti­body tislelizum­ab state­side, Chi­na-based BeiGene is mak­ing a sim­i­lar play in re­verse.

On Wednes­day evening, BeiGene took the wraps off a $120 mil­lion-plus deal with Boston Im­mune Tech­nolo­gies and Ther­a­peu­tics to de­vel­op and com­mer­cial­ize their tu­mor necro­sis fac­tor re­cep­tor 2 (TN­FR2) an­tag­o­nist an­ti­bod­ies in Asia (ex­clud­ing Japan), Aus­tralia and New Zealand.

Lu­song Luo

The deal is part of BeiGene’s strat­e­gy to build out its on­col­o­gy pipeline by bring­ing in ex­ter­nal can­di­dates, SVP of ex­ter­nal in­no­va­tions Lu­song Luo told End­points News. 

“This is a lit­tle bit dif­fer­ent from the No­var­tis deal we did ear­ly on this year … and so that is kind of a re­verse,” Luo said.

Rather than tak­ing an in-house can­di­date abroad, the com­pa­ny is bring­ing in BITT’s lead an­ti­body and launch­ing it in­to Phase I monother­a­py and com­bi­na­tion tri­als with tislelizum­ab. The lat­ter an­ti­body ar­rived on the Chi­nese mar­ket among a wave of PD-1 check­point in­hibitors in late 2019, and was the cen­ter of a mul­ti-bil­lion dol­lar No­var­tis deal last month.

“The com­mon de­nom­i­na­tor is we are try­ing to bring ex­ter­nal in­no­va­tions in, and al­so bring our in­no­va­tions out to oth­er ge­o­graph­i­cal re­gions,” Luo added.

BeiGene is putting down $16.6 mil­lion in up­front and near-term mile­stone pay­ments, though Luo de­clined to break that fig­ure down any fur­ther. BITT stands to make up to an­oth­er $105 mil­lion in fur­ther mile­stones, and tiered roy­al­ties on sales in the li­censed ter­ri­to­ries. And BeiGene sweet­ened the deal by toss­ing in an­oth­er $4 mil­lion to BITT’s Se­ries A.

Luo says BeiGene is in­ter­est­ed in TN­FR2 for mul­ti­ple rea­sons, the first be­ing that it’s “one of the most abun­dant kinds of mark­ers for the im­muno­sup­pres­sive tu­mor mi­croen­vi­ron­ment,” and is high­ly ex­pressed on reg­u­la­to­ry T cells. It’s al­so a broad­ly ex­pressed sur­face onco­gene.

TN­FR2 is a mem­ber of the TNF re­cep­tor su­per­fam­i­ly — block­buster Hu­mi­ra, for ex­am­ple, tar­gets a dif­fer­ent mem­ber of the fam­i­ly — that has been shown to pro­lif­er­ate tu­mor growth. It’s al­so ex­pressed on sup­pres­sive im­mune cells, and has been iden­ti­fied as a po­ten­tial dri­ver of im­mune es­cape and re­sis­tance to the check­point block­ade.

“BITT TN­FR2 an­ti­bod­ies are an­tag­o­nists that bind to a se­lect re­gion of the TN­FR2 re­cep­tor for can­cer and Treg in­hib­it­ed growth,” BeiGene said in a state­ment.

The com­pa­ny will need to catch up with Swedish BioIn­vent, which un­veiled its own broad an­ti-TN­FR2 pro­gram to treat sol­id tu­mors back in 2019 and al­ready has a can­di­date in Phase I. It al­so has an­oth­er TN­FR2 can­di­date in pre­clin­i­cal de­vel­op­ment.

While Luo de­clined to com­ment on BeiGene’s clin­i­cal time­line, he said they plan to launch Phase I tri­als “in the near fu­ture.”

The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Before diving in, we had some news to share: Endpoints is launching a premium weekly report focusing on all things regulatory. Coverage will be led by our new senior editor, Zachary Brennan, who joins us from POLITICO. Arsalan Arif has more details in his Publisher’s Note.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Robert Bradway (Photographer: Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Am­gen snaps up can­cer drug play­er Five Prime, adding PhI­II-ready FGFR2b drug in $2B M&A play

Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion and adding a slate of new cancer drugs to the pipeline.

Amgen is paying $38 a share, putting the deal value at $1.9 billion. The stock closed at $21.26 last night, giving investors a 78% premium.

The jewel in the crown of this deal is bemarituzumab, which Amgen describes as a first-in-class, Phase III-ready anti-FGFR2b antibody. Amgen was drawn to the bargaining table by Five Prime’s mid-stage data on gastric cancer, satisfied by PFS and OS data helping to validate FGFR2b as a target. Amgen researchers will now expand on the R&D program in other epithelial cancers, including lung, breast, ovarian and other cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The global pandemic may have roiled economies, killed hundreds of thousands and throttled entire industries, but the only effect it had on biopharma venture investing was to help turbocharge the field to giddy new heights.

Below you’ll find the new top 100 venture investors in the industry, ranked by the number of deals they were publicly involved in, as tracked by DealForma chief Chris Dokomajilar. The numbers master then calculated the estimated amount of money they put into each deal — divvying up the cash by the number of players — to indicate how they managed their syndicates.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Liu (Casey Atkins Photography courtesy Broad Institute)

David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing pro­teins

Before David Liu became famous for inventing new forms of gene editing, he was known around academia in part for a more obscure innovation: a Rube Goldberg-esque system that uses bacteria-infecting viruses to take one protein and turn it into another.

Since 2011, Liu’s lab has used the system, called PACE, to dream up fantastical new proteins: DNA base editors far more powerful than the original; more versatile forms of the gene editor Cas9; insecticides that kill insecticide-resistant bugs; enzymes that slide synthetic amino acids into living organisms. But they struggled throughout to master one of the most common and powerful proteins in the biological world: proteases, a set of Swiss army knife enzymes that cut, cleave or shred other proteins in everything from viruses to humans.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bruce Cozadd, Jazz CEO (Jazz Pharmaceuticals)

Jazz CEO Bruce Cozadd cam­paigned for 6 months to buy GW Phar­ma. A 90% pre­mi­um sealed the deal — along with $17.6M in ‘re­ten­tion’ in­cen­tives

Jazz CEO Bruce Cozadd didn’t beat around the bush.

In his first video meeting with GW Pharma chief Justin Gover last July 8, he offered to pay $172 a share to get the company, which had beaten the odds in getting its remarkable cannabinoid drug Epidiolex across the regulatory finish line for epilepsy. GW’s stock closed at $129 that day.

Cozadd had already done his homework on the financing to make sure he could swing it the way he wanted. He just needed to do some due diligence before making the non-binding bid firm.

Af­ter three years of courtship (and turn­downs), Mer­ck pounced on the first glance of clin­i­cal da­ta in $1.85B Pan­dion takeover

It’s almost become cliché for biotech executives to talk about the importance of keeping your options open and being prepared to go all the way. But when it comes to negotiating with a giant like Merck, a little patience can indeed go a long way.

Just ask Pandion Therapeutics.

Days ago we already learned that Merck is shelling out $1.85 billion to pick up the biotech and its slate of autoimmune hopefuls. What we didn’t know until the SEC disclosure dropped Thursday is that the deal comes after Pandion turned down two other proposals from Merck over the past three years and held out until the last minute for a sweetened deal.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

Soticlestat made it.

Takeda is bringing the drug back into its fold more than four years after first entrusting the team at Ovid with the mid-stage clinical work. For all that — generating what they saw as positive Phase II data in Dravet syndrome and Lennox-Gastaut syndrome — the biotech has been rewarded with $196 million in upfront cash, with another $660 million reserved for regulatory and commercial milestones.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Not 3 weeks af­ter tak­ing Hu­ma­cyte pub­lic, Ra­jiv Shuk­la launch­es an­oth­er blank check com­pa­ny

One of biotech’s earliest SPAC investors is back with another blank-check company, less than a month after his last effort announced its intent to merge.

Rajiv Shukla is intending to take a third lucky winner public with Alpha Healthcare Acquisition III, filing to go public Thursday with a $150 million raise penciled in. The move comes just a couple of weeks after Shukla’s second SPAC said it would jump to Nasdaq in tandem with Laura Niklason’s Humacyte in a $255 million new investment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Getty Images

How does Paul Hud­son's $13.5M comp pack­age stack up against oth­er CEOs? He's in the 'first quar­tile'

Paul Hudson arrived at Sanofi like a hurricane, chopping off duds in the pipeline, shaking up the C-suite, striking big M&A deals and jumping into the Covid-19 vaccine race — all in an attempt to reboot a pharma giant notorious for its setbacks.

Now, we’re getting a look at what the CEO brought home in his first year on the job.

When all is said and done, Hudson will have made about $6.7 million in 2020, about $2.5 million of which has already been paid. The bigger figure includes a $2.3 million bonus that’s subject to approval at an April meeting, and another $1.8 million in variable compensation that has yet to be paid.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.